Matinas BioPharma Holdings (MTNB) Analysts See $-0.05 EPS; Natco Group Has 1 Sentiment

November 15, 2017 - By Ellis Scott

Analysts expect Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) to report $-0.05 EPS on November, 21.They anticipate $0.06 EPS change or 54.55% from last quarter’s $-0.11 EPS. After having $-0.04 EPS previously, Matinas BioPharma Holdings Inc’s analysts see 25.00% EPS growth. It closed at $1.14 lastly. It is down 469.23% since November 15, 2016 and is uptrending. It has outperformed by 452.53% the S&P500.

Tortoise MLP Fund, Inc. is a non-diversified, closed-end management investment company. The company has market cap of $777.21 million. The Fund’s primary investment objective is to seek a high level of total return with an emphasis on current distributions. It currently has negative earnings. It invests primarily in master limited partnerships and their affiliates that own and operate a network of pipeline and energy-related logistical infrastructure assets.

Oxbow Advisors Llc holds 1.59% of its portfolio in Tortoise MLP Fund, Inc. for 466,248 shares. Arete Wealth Advisors Llc owns 155,979 shares or 1.37% of their US portfolio. Moreover, Anderson Hoagland & Co has 1.31% invested in the company for 105,997 shares. The Wisconsin-based Northern Capital Management Llc has invested 0.8% in the stock. Bard Associates Inc, a Illinois-based fund reported 77,882 shares.

The stock decreased 1.95% or $0.32 on November 14, reaching $16.12. About shares traded. Tortoise MLP Fund, Inc. (NTG) has risen 10.59% since November 15, 2016 and is uptrending. It has underperformed by 6.11% the S&P500.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $105.57 million. The Firm is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It currently has negative earnings. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>